407 related articles for article (PubMed ID: 25916979)
1. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
[TBL] [Abstract][Full Text] [Related]
2. Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma.
Minato T; Yamamoto Y; Seike J; Yoshida T; Yamai H; Takechi H; Yuasa Y; Furukita Y; Goto M; Bando Y; Tangoku A
Ann Surg Oncol; 2013 Jan; 20(1):209-17. PubMed ID: 22847125
[TBL] [Abstract][Full Text] [Related]
3. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer.
Alamgeer M; Ganju V; Kumar B; Fox J; Hart S; White M; Harris M; Stuckey J; Prodanovic Z; Schneider-Kolsky ME; Watkins DN
Breast Cancer Res; 2014 Apr; 16(2):R44. PubMed ID: 24762066
[TBL] [Abstract][Full Text] [Related]
4. Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer.
Zhou L; Yu L; Zhu B; Wu S; Song W; Gong X; Wang D
BMC Cancer; 2016 Nov; 16(1):876. PubMed ID: 27832750
[TBL] [Abstract][Full Text] [Related]
5. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
[TBL] [Abstract][Full Text] [Related]
6. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
[TBL] [Abstract][Full Text] [Related]
7. Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications.
Rahadiani N; Ikeda J; Mamat S; Matsuzaki S; Ueda Y; Umehara R; Tian T; Wang Y; Enomoto T; Kimura T; Aozasa K; Morii E
Cancer Sci; 2011 Apr; 102(4):903-8. PubMed ID: 21231983
[TBL] [Abstract][Full Text] [Related]
8. Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy.
Lee JY; Kim YH; Kim MJ; Kim K; Chung HH; Park NH; Song YS; Kang SB
Arch Gynecol Obstet; 2011 Aug; 284(2):477-82. PubMed ID: 20878172
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.
Chen H; Liang C; Zhang L; Huang S; Wu X
Gynecol Oncol; 2008 Sep; 110(3):308-15. PubMed ID: 18606439
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo expression of aldehyde dehydrogenase 1 in oral squamous cell carcinoma.
Ota N; Ohno J; Seno K; Taniguchi K; Ozeki S
Int J Oncol; 2014 Feb; 44(2):435-42. PubMed ID: 24285422
[TBL] [Abstract][Full Text] [Related]
11. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.
Yin M; Zhang H; Li H; Li X; Liu Y; Chen X; Lou G; Li K
J Surg Oncol; 2012 Feb; 105(2):206-11. PubMed ID: 21815150
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix.
Serur E; Mathews RP; Gates J; Levine P; Maiman M; Remy JC
Gynecol Oncol; 1997 May; 65(2):348-56. PubMed ID: 9159350
[TBL] [Abstract][Full Text] [Related]
13. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma.
Costa S; Terzano P; Bovicelli A; Martoni A; Angelelli B; Santini D; Ceccarelli C; Lipponen P; Erzén M; Syrjänen S; Syrjänen K
Gynecol Oncol; 2001 Jan; 80(1):67-73. PubMed ID: 11136572
[TBL] [Abstract][Full Text] [Related]
14. Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility.
Distefano M; Ferrandina G; Smaniotto D; Margariti AP; Zannoni G; Macchia G; Manfredi R; Mangiacotti MG; Cellini N; Scambia G
Oncology; 2004; 67(2):103-11. PubMed ID: 15539913
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of neoadjuvant chemotherapy plus radical surgery in patients with bulky stage II cervical squamous cell carcinoma: A retrospective cohort study.
Qin T; Zhen J; Zhou M; Wu H; Ren R; Qu B; Wang H
Int J Surg; 2016 Jun; 30():121-5. PubMed ID: 27131759
[TBL] [Abstract][Full Text] [Related]
16. Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy.
Watari H; Kanuma T; Ohta Y; Hassan MK; Mitamura T; Hosaka M; Minegishi T; Sakuragi N
Pathol Oncol Res; 2010 Sep; 16(3):345-52. PubMed ID: 20058210
[TBL] [Abstract][Full Text] [Related]
17. Aldehyde dehydrogenase 1 (ALDH1) positivity correlates with poor prognosis in cervical cancer.
Yao T; Wu Z; Liu Y; Rao Q; Lin Z
J Int Med Res; 2014 Aug; 42(4):1038-42. PubMed ID: 24827824
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.
Sugiyama T; Nishida T; Hasuo Y; Fujiyoshi K; Yakushiji M
Gynecol Oncol; 1998 May; 69(2):130-6. PubMed ID: 9600820
[TBL] [Abstract][Full Text] [Related]
19. Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy.
Takatori E; Shoji T; Omi H; Kagabu M; Miura F; Takeuchi S; Kumagai S; Yoshizaki A; Sato A; Sugiyama T
Int J Clin Oncol; 2015 Apr; 20(2):345-50. PubMed ID: 24825458
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer.
Ayub TH; Keyver-Paik MD; Debald M; Rostamzadeh B; Thiesler T; Schröder L; Barchet W; Abramian A; Kaiser C; Kristiansen G; Kuhn W; Kübler K
Oncotarget; 2015 Jun; 6(18):16437-48. PubMed ID: 25999351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
